IDEAYA Biosciences Stock - weekly outlook after muted technicals

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 18:06 UTC. Details in the imprint.

IDEAYA Biosciences (US45166A1025) starts the weekend with a technical review rather than a fresh corporate hook. TradingKey places the stock at $31.230 as of 06/18/2026, with a market cap of $2.74 billion.

What the tape shows

IDYA shares were last quoted at $31.230 on 06/18/2026 at 16:00 ET, according to TradingKey. The same source puts the market cap at $2.74 billion and shows the stock down 0.10% on the session.

MarketBeat says IDEAYA last reported quarterly earnings on 05/05/2026. It lists EPS of -$1.11, below the consensus estimate of -$1.07, and says revenue fell 39.4% year over year.

Chart levels to watch

TradingKey frames the shares as range-bound between resistance at $33.44 and support at $27.91. It also says the current momentum score is 8.52, with three buy signals and one sell signal in its technical model.

That setup fits a quiet weekend view more than a catalyst-driven one. For now, the move is defined by the range, not by a fresh company announcement.

What the company develops

IDEAYA is a precision medicine oncology company. Its pipeline centers on targeted therapies for cancer, with research programs built around synthetic lethality and biomarker-driven development.

Where the stock trades today

The shares of IDEAYA Biosciences (US45166A1025) trade on Nasdaq at $31.230 as of 06/18/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.